02:28 AM EDT, 09/22/2026 (MT Newswires) -- Oxford Biomedica (OXB.L) said Tuesday that its loss for the first half increased, while revenue jumped year over year. Loss attributable to owners of the company for the six months ended June 30 was 37.0 million pounds sterling, compared with a loss of 26.4 million pounds earlier. Loss per share moved to 0.3039 pound from 0.2535 pound. The cell and gene therapy company's revenue was 79.8 million pounds, compared with 73.2 million pounds a year ago. Looking ahead, Oxford Biomedica continues to forecast a constant-currency revenue of between 180 million pounds and 200 million pounds for full-year 2026. It also maintained its annual revenue growth guidance of 25% to 30% for 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.